Mild cognitive impairment: Potential therapeutics;Le déclin cognitif modéré ou le mild cognitive impairment (MCI): Perspectives thérapeutiques

Revue Neurologique

Volumn 158, Issue 10 SUPPL., 2002, Pages

  Allain, H ^a   Bentue Ferrer, D ^a   Belliard, S ^b   Reymann, J M ^a   Djemai M ^c   Merienne, M ^c  

^a UNIVERSITÉ DE RENNES 1   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^c Biotrial SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CHOLINESTERASE INHIBITOR; NOOTROPIC AGENT; ALPHA TOCOPHEROL; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; MEMORY; PROBABILITY; REVIEW; AGED; HOSPITALIZATION; NEUROPSYCHOLOGICAL TEST;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DOPAMINE AGONISTS; HUMANS; INDANS; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; SEVERITY OF ILLNESS INDEX; VITAMIN E;

EID: 0036445883     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Allain H, Bentue-Ferrer D, Decombe R. (1990a). Choosing a target for cognitive enhancers. Clin Ther, 12: 4.
2. Allain H, Lieury A, Reymann JM, et al. (1990b). Le développement des médicaments promnésiants. Ann Med Intern (Paris), 141 (Suppl 1): 19-25.
3. Allain H, Belliard S, De Certaines J, Bentue-Ferrer D, Bureau M, Lacroix P. (1993a). Potential biological targets for anti-Alzheimer drugs. Dementia, 4: 347-352.
4. Allain H, Raoul P, Lieury A, Lecoz F, Gandon JM. (1993b). Effect of two doses of Ginkgo Biloba extract (Egb 761) on the dual-coding test in elderly subjects. Clin Ther. 15: 549-557.
5. Allain H, Lieury A, Belliard S, Caldwell M, Patat A, Gandon JM. (1996). Effect of drugs on mnestic performance: A methodological approach. Hum Psychopharmacol, 11: 11-19.
6. Allain H, Neuman E, Malbezin M, et al. (1997). Bridging study of S 12024 in 53 in-patients with Alzheimer's disease. JAGS, 45: 125-126.
7. Allain H, Tribut O, Reymann JM, Polard E, Le Cavorzin P, Bentue-Ferrer D. (2001a). Perspectives medicamenteuses dans la maladie d'Alzheimer. Ann Med Intern, 152: 527-532.
8. Allain H, Schück S, Mauduit N, Djemaï M. (2001b). Comparative effects of pharmacotherapy on the maintenance of cognitive functions. Eur Psychiatry, 16: 35s-41s.
9. Allain H. (2001c). Propriétés pharmacologiques et pharmacocinétiques du piribédil. Dis Manage Health Outcomes, 9 (Suppl 1): 41-48.
10. Barnes CA, Meltzer J, Houston F, Orr G, McGann K, Wenk GL. (2000). Chronic treatment of old rats with donepezil or galantamine: Effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience, 99: 17-23.
11. Chapoutier G. (1994). La biologie de la mémoire. PUF (Paris), pp. 128.
12. Cutler NR, Sramek JJ, Seifert RD, Conrad JJ, Wardle TS. (1995). The safety and tolerance of xanomeline tartrate, a M1-specific cholinergic agonist, in patients with Alzheimer's disease. In: Alzheimer's and Parkinson's Diseases. Hanin I, et aL Eds. Plenum Press (New York). USA, pp. 479-482.
13. Cutler NR, Sramek JJ. (2001). Review of the next generation of Alzheimer's disease therapeutics: Challenges for drug development. Prog Neuro-Psychopharmacol & Biol Psychiatr, 25: 73-89.
14. 18F] fluoro-2-deoxy-D-glucose/position emission tomography (FDG/PET). PNAS, 98: 10966-10971.
15. Djemaï-Zoghloache M, Burger K, Schück S, Moller HJ. (2000). Thérapie multiconceptuelle dans la maladie d'Alzheimer, Presse Med, 29: 1197-1201.
16. Doody RS, Stevens JC, Beck C, et al. (2001). Practice parameter: Management of dementia (an evidence-based review). Neurology, 56: 1154-1166.
17. Esler W, Wolfe M. (2001). A portrait of Alzheimer secretases - New features and familiar faces. Science, 293: 1449-1454.
18. Finkel E. (2001). The mitochondrion: Is it central to apoptosis? Science, 292: 624-626.
19. Finkel T, Holbrook NJ. (2000). Oxidants, oxidative stress and the biology of ageing. Nature, 408: 239-247.
20. Fox NC, Freeborough PA. (1997). Brain atrophy progression measured from registered serial MRI: Validation and application to Alzheimer's disease. J Magn Reson Imaging, 7: 1069-1075.
21. Gauthier S. (2001). Alzheimer's disease: Current and future therapeutic perspectives. Prog Neuro-Psychopharmacol & Biol Psychiatr, 25: 73-89.
22. Grundman M. (2000). Vitamine E and Alzheimer's Disease: The basis for additional clinical trials. Ann J Clin Nutr, 71 (Suppl): 630s-636s.
23. Hashimoto Y, Niikura T, Tajima H, et al. (2001). A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ. PNAS, 98: 6336-6341.
24. Hogan DB, McKeith IG. (2001). Of MCI and dementia: Improving diagnosis and treatment. Neurology, 56: 1131-1132.
25. Horner PJ, Gage FH. (2000). Regenerating the damaged central nervous system. Nature, 407: 963-970.
26. Hughes CP, Berg L, Danzinger WL, et al. (1982). A new clinical scale for the staging of dementia. Br J Psychiatry, 140: 566-572.
27. Jack CR, Petersen RC, Xu YC, et al. (1997). Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology, 49: 786-794.
28. Jones S, Sudweek S, Yakel JL. (1999). Nicotinic receptors in the brain: Correlating physiology with function. TINS, 22: 555-561.
29. Jack CR, Petersen RC, Xu YC, et al. (1999). Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology, 52: 1397-1403.
30. Kapur S, Zipursky R, Jones C, Remington G, Houle S. (2000). Relationship between dopamine D2 occupancy, clinical response, and side-effects: A double blind PET study of first episode schizophrenia. Am J Psychiatry, 157: 514-520.
31. Levy R, for the Aging-Associated Cognitive Decline Working Party. (1994). Aging-associated cognitive decline. Int Psychogeriatr, 6: 63-68.
32. Morain P, Robin JL, De Nanteuil G, Jochemsen R, Heidet V, Guez D. (2000). Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. Br J Clin Pharmacol, 50: 350-359.
33. Mufson EJ, Chen EY, Cochran EJ, Beckett LA, Kordower JH. (1999). Entorrhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol, 158: 469-490.
34. Nagaraja D, Jayashree S. (2001). Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry, 158: 1517-1519.
35. Owens J. (2001). Milking nature for Alzheimer's treatment. Drug Discovery Today, 17: 866-868.
36. Patat A. (2000). Clinical pharmacology of psychotropic drugs. Hum Psychopharmacol, 15: 361-387.
37. Perry EK, Perry RH. (1995). Acetylcholine and hallucinations: Disease related compared to drug-induced alterations in human consciousness. Brain Cogn, 28: 240-258.
38. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. (1999). Mild cognitive impairment: Clinical characterisation and outcome. Arch Neurol, 56: 303-308.
39. Petersen RC, Stevens J, Ganguli M, Tangalos EG, Cummings J, Dekosky ST. (2001). Practice parameter: Early detection of dementia; mild cognitive impairment (an evidence-based review). Neurology, 56: 1133-1142.
40. Richtie K, Touchon J. (2000). Mild cognitive impairment: Conceptual basis and current nosological status. Lancet, 355: 225-228.
41. Richtie K, Artero S, Touchon J. (2001). Classification criteria for mild cognitive impairment: A population-based validation study. Neurology, 56: 37-42.
42. Sansom G. (2000). Modulating AMPA receptors: Key to mild cognitive impairment and memory. Drug Discovery Today, 5: 441-442.
43. Schück S, Bentue-Ferrer D, Reymann JM, et al. (2002). Psychomotor and cognitive effects of piribedil, a dopamine agonist in young healthy volunteers. Fundam Clin Pharmacol, 16: 57-65.
44. Shah Y, Tangalos EG, Petersen RC. (2000). Mild cognitive impairment: When is it a precursor to Alzheimer's disease? Geriatrics, 55: 62-68.
45. Sherwin BB. (2000). Mild cognitive impairment: Potential pharmacological treatment options. JAGS, 48: 431-441.
46. Sramek JJ, Anand R, Wardle TS, Irwin P, Hartman RD, Cutler NR. (1996). Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci, 58: 1201-1207.
47. Sramek JJ, Veroff AE, Cutler NR. (2000). Mild cognitive impairment: Emerging therapeutics. Ann Pharmacother, 34: 1179-1188.
48. Wan SD. (1994). The presence of glycated tau in Alzheimer's disease: A mechanism for induction of oxidant stress. PNAS (USA), 91: 7787-7791.
49. Wang KKW. (2000). Calpain and Caspase: Can you tell the difference? TINS, 23: 20-26.